Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab".
Saved in:
| Title: | Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab". |
|---|---|
| Authors: | Gerischer, Lea1,2 (AUTHOR) lea.gerischer@charite.de, Schroeder‐Braunstein, Jutta3 (AUTHOR), Wabnitz, Guido3 (AUTHOR), Meisel, Andreas1,2,4 (AUTHOR) |
| Source: | Annals of Clinical & Translational Neurology. Jun2026, Vol. 13 Issue 6, p1303-1304. 2p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
